rs10514299 — TMEM161B-MEF2C TMEM161B-MEF2C intergenic variant

Intronic variant near the MEF2C transcription factor locus associated with increased risk of major depressive disorder through altered neuronal synapse regulation

See your personal result for TMEM161B-MEF2C

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Synapse Sculptor — MEF2C and the Genetics of Depression

Not all depression has the same biological roots. For roughly one in four people of European ancestry who carry at least one copy of the T allele at rs10514299, a portion of that vulnerability may trace back to the MEF2C locus11 MEF2C locus
Myocyte enhancer factor 2C — a transcription factor that acts as a master regulator of synapse number, neuronal survival, and activity-dependent plasticity in the developing and adult brain on chromosome 5q14.3. This variant sits within a non-coding RNA transcript (TMEM161B-DT) immediately adjacent to MEF2C, where it is thought to influence MEF2C expression levels in brain tissue. The discovery of this locus, confirmed at P = 9.99 × 10−16 in the largest depression GWAS conducted at the time, placed MEF2C at the center of the emerging genetics of mood disorders.

The Mechanism

MEF2C belongs to the MADS-box family of transcription factors and is one of the earliest-expressed MEF2 isoforms in the developing telencephalon. It plays a central role in controlling excitatory synapse number through activity-dependent synapse elimination22 activity-dependent synapse elimination
When neurons fire, calcium signaling activates calcineurin, which dephosphorylates MEF2C, switching it from a repressor to an activator of synapse-pruning genes such as Pcdh10. In this way, MEF2C acts as a negative regulator of synaptogenesis — constraining the number of excitatory connections to maintain proper excitatory/inhibitory balance.

When MEF2C function is reduced — as the T allele at rs10514299 may cause via altered regulatory element activity — excitatory synapse pruning is impaired, disrupting cortical and hippocampal circuit calibration. Mouse models with conditional Mef2c knockout in excitatory neurons show dramatically reduced network activity, anxiety-like behavior, and cognitive deficits, mirroring phenotypes relevant to depression. MEF2C also regulates neuronal differentiation, axon guidance, and activity-dependent survival — making it a broad-spectrum orchestrator of the neural circuitry that underlies mood regulation.

Pharmacologically, this pathway is relevant beyond genetics: HDAC inhibitors33 HDAC inhibitors
Histone deacetylase inhibitors increase histone acetylation, promoting the transcription of MEF2C target genes. Valproate — used as a mood stabilizer — is a Class I/II HDAC inhibitor; part of its mood-stabilizing effect may operate through MEF2C-dependent transcription. Valproate (valproic acid) is a known Class I/II HDAC inhibitor, and some of its therapeutic effect in mood disorders may work partly through MEF2C-dependent transcriptional activation.

The Evidence

Discovery — Hyde et al. 2016. The first large-scale depression GWAS using 23andMe data44 The first large-scale depression GWAS using 23andMe data
Hyde CL et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nature Genetics, 2016 combined data from 75,607 cases and 231,747 controls in a discovery phase, then replicated in 45,773 cases and 106,354 controls. rs10514299 reached a joint p-value of 9.99 × 10−16 — one of the most statistically robust findings in that landmark study. The locus harbored two independent significant signals (rs10514299 and rs454214), suggesting the MEF2C region contains multiple functional elements contributing to depression risk.

Validation — Howard et al. 2019. A meta-analysis of 807,553 individuals55 A meta-analysis of 807,553 individuals
Howard DM et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 2019 (246,363 cases and 561,190 controls) identified 102 independent variants and 269 genes. MEF2C appeared in 10 of the 15 most significant biological gene-sets associated with depression, including GO_EXCITATORY_SYNAPSE, GO_POSTSYNAPSE, and GO_NEURON_SPINE — reinforcing that synaptic regulation at the MEF2C locus is not incidental but central to the biology of MDD.

Functional readout — Muench et al. 2018. A neuroimaging study in alcohol-dependent patients66 A neuroimaging study in alcohol-dependent patients
Muench C et al. The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence. Translational Psychiatry, 2018 demonstrated that T allele carriers (n=45 patients vs. 45 controls) showed significantly greater putamen activation during reward anticipation (p=0.014) and loss anticipation (p=0.024–0.046). The putamen is a key node in the reward circuitry; its hyperactivation in T allele carriers provides a direct functional bridge between the GWAS finding and disrupted reward processing — a hallmark of depressive episodes.

Effect size context. The odds ratio for rs10514299 is approximately 1.05 per T allele in European ancestry populations — modest for any individual but consistent, replicated, and mechanistically coherent. Depression is highly polygenic; this variant represents one of dozens of genome-wide significant contributors.

Practical Implications

Carrying T alleles at this locus does not cause depression, but it does represent a real, biologically grounded increment in susceptibility — particularly through disrupted synaptic calibration and reward circuit regulation. The actionable insight is targeted: strategies that support MEF2C-pathway resilience include interventions with documented neuroplasticity effects. Physical exercise increases MEF2C expression77 increases MEF2C expression
Chen SX et al. demonstrated that voluntary running upregulates Mef2c mRNA in hippocampal neurons in rodent models, suggesting exercise partially restores MEF2C pathway activity in hippocampal tissue via BDNF-dependent signaling, connecting one of the most evidence-supported depression interventions to this specific locus.

If prescribed a mood stabilizer, valproate (valproic acid) is mechanistically relevant because its HDAC-inhibiting activity upregulates MEF2C target gene transcription — a convergence between pharmacology and the genetic vulnerability encoded at this locus.

Interactions

The TMEM161B-MEF2C locus contains two independent GWAS signals: rs10514299 and the companion variant rs454214 (in MEF2C-AS2, the antisense RNA adjacent to MEF2C). Individuals carrying risk alleles at both loci may experience a cumulative effect from the same pathway. The broader MEF2C biology intersects with dopamine signaling: MEF2C regulates striatal synapse development, and SNPs in dopaminergic genes (rs1800497 DRD2/ANKK1, rs4680 COMT) may compound vulnerability through overlapping reward circuitry mechanisms.

Genotype Interpretations

What each possible genotype means for this variant.

CC Low Depression Risk (MEF2C) Normal

No T alleles — typical MEF2C-pathway depression risk

The CC genotype at rs10514299 indicates no copies of the T risk allele identified in the Hyde 2016 (PMID 27479909) and Howard 2019 (PMID 30718901) large-scale depression GWAS studies. Because the T allele acts additively, the CC genotype represents the lowest-risk tier at this locus. Depression remains a complex, polygenic condition influenced by many other loci and non-genetic factors; this result addresses only this one of 102+ known genetic contributors.

CT Moderate Depression Risk (MEF2C) Intermediate

One T allele — modestly elevated MEF2C-pathway depression risk

The CT genotype confers a single copy of the rs10514299 T allele, which was associated with depression at P = 9.99 × 10−16 in a joint analysis of over 450,000 individuals (Hyde et al. 2016, PMID 27479909) and validated in the Howard 2019 meta-analysis of 807,553 individuals (PMID 30718901). The biological mechanism involves MEF2C — a master regulator of excitatory synapse number in the hippocampus and cortex. Functional imaging data (Muench 2018, PMID 30006604) show that T allele carriers exhibit hyperactivated reward circuitry in the putamen, consistent with the reward processing disruptions seen in depressive episodes.

The effect is additive: CT carriers have an intermediate risk profile between CC (no elevation) and TT (two copies of the risk allele). The OR of ~1.05 is modest in absolute terms but has been replicated across multiple independent cohorts and ethnicities. This variant contributes to overall polygenic depression risk.

TT Elevated Depression Risk (MEF2C) High Risk

Two T alleles — elevated MEF2C-pathway depression risk with reward circuit implications

The TT genotype represents homozygous carriage of the rs10514299 depression risk allele — the highest-risk tier at this locus. The T allele is thought to reduce MEF2C regulatory activity, impairing the normal activity-dependent pruning of excitatory synapses in the hippocampus and prefrontal cortex. This disrupts the excitatory/inhibitory balance that underlies stable mood regulation and cognitive function. Howard et al. 2019 (PMID 30718901) placed MEF2C in 10 of 15 depression-associated biological gene-sets, underscoring that this is not a peripheral association but a central mechanistic locus for the genetic architecture of major depressive disorder.

Muench et al. 2018 (PMID 30006604) found that T allele carriers in a neuroimaging cohort showed significantly greater putamen hyperactivation during both reward anticipation (p=0.014) and loss anticipation (p=0.024–0.046) — a pattern of aberrant salience processing that maps onto the anhedonia and motivational impairment central to depression. The T allele was also associated with greater depression symptom severity in African American individuals with alcohol dependence (β=2.11, p=0.008).

Important caveat: depression is highly polygenic, and this variant is one of 102+ genome-wide significant contributors. A TT genotype here is not a diagnosis or a prediction of inevitable illness. It is a biologically meaningful increment in risk that warrants proactive monitoring and, if symptoms arise, informed clinical engagement.